Biotech Stock Hate Mailbag: The Hostile React-o-Meter Meltdown Edition

NEW YORK ( TheStreet) -- An admission right up front: This Biotech Stock Mailbag has no educational value whatsoever. It's mindless fluff. A throwaway column. But with the disclaimer aside, I've been getting so much hate mail and nasty tweets lately, I thought it would be fun to throw a representative samper into a single column for funny Friday read. There's probably something deeper to be said about market psychology and what an uptick in hate mail means for biotech investor sentiment, but I'll leave the interpretations up to you. 

Let's start with some nasty tweets pertaining to my coverage of Provectus Pharmaceuticals (PVCT). In particular, one tweep appears to enjoy playing with Photoshop:

This guy didn't like my column comparing MannKind (MNKD) to Arena Pharmaceuticals (ARNA). I suspect he also commits most of the Seven Deadly Sins of Biotech Investing.

If you liked this article you might like

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind Stock Drops Following Changes to Its Insulin Product

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Insulin Drug Offers Hope for MannKind